Adalimumab for induction of clinical remission in moderately to severely active ulcerative colitis: Results of a randomised controlled trial

Gut

Volumn 60, Issue 6, 2011, Pages 780-787

  Reinisch, Walter ^a   Sandborn, William J ^b   Hommes, Daniel W ^c   D'Haens, Geert ^d   Hanauer, Stephen ^e   Schreiber, Stefan ^f   Panaccione, Remo ^g   Fedorak, Richard N ^h   Tighe, Mary Beth ⁱ   Huang, Bidan ⁱ   Kampman, Wendy ^j   Lazar, Andreas ^k   Thakkar, Roopal ⁱ  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b MAYO CLINIC   (United States)

^c LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^d ACADEMIC MEDICAL CENTER   (Netherlands)

^e UNIVERSITY OF CHICAGO MEDICAL CENTER   (United States)

^f UNIVERSITY OF KIEL   (Germany)

^g UNIVERSITY OF CALGARY   (Canada)

^h UNIVERSITY OF ALBERTA   (Canada)

ⁱ ABBOTT LABORATORIES   (United States)

^j ABBOTT LABORATORIES   (United Kingdom)

^k ABBOTT GMBH AND CO KG   (Germany)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; PLACEBO;

ARTICLE; CLINICAL ASSESSMENT; CONGESTIVE HEART FAILURE; CONTROLLED STUDY; DEMYELINATING DISEASE; DISEASE DURATION; DISEASE SEVERITY; DRUG EFFICACY; DRUG FATALITY; DRUG SAFETY; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; HUMAN; INFECTION; INJECTION SITE PAIN; LUPUS LIKE SYNDROME; MULTICENTER STUDY; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REMISSION; SCORING SYSTEM; TREATMENT RESPONSE; TUBERCULOSIS; ULCERATIVE COLITIS;

ADOLESCENT; ADULT; AGED; ANTIBODIES, MONOCLONAL; COLITIS, ULCERATIVE; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; FEMALE; GASTROINTESTINAL AGENTS; HUMANS; MALE; MIDDLE AGED; REMISSION INDUCTION; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA; YOUNG ADULT;

EID: 79955859430     PISSN: 00175749     EISSN: 14683288     Source Type: Journal    
DOI: 10.1136/gut.2010.221127     Document Type: Article

References (23)

1. Rubin DT, Dubinsky MC, Panaccione R, et al. The impact of ulcerative colitis on patients' lives compared to other chronic diseases: a patient survey. Dig Dis Sci 2010;55:1044-52.
2. Cohen RD, Yu AP, Wu EQ, et al. Systematic review: costs of ulcerative colitis in western countries. Aliment Pharmacol Ther 2010;31:693-707.
3. Baumgart DC, Targan SR, Dignass AU, et al. Prospective randomized open-label multicenter phase I/II dose escalation trial of visilizumab (HuM291) in severe steroidrefractory ulcerative colitis. Inflamm Bowel Dis 2010;16:620-9.
4. Van Assche G, Sandborn WJ, Feagan BG, et al. Daclizumab, a humanised monoclonal antibody to the interleukin 2 receptor (CD25), for the treatment of moderately to severely active ulcerative colitis: a randomised, double blind, placebo controlled, dose ranging trial. Gut 2006;55:1568-74. (Pubitemid 44629204)
5. Feagan BG, Greenberg GR, Wild G, et al. Treatment of ulcerative colitis with a humanized antibody to the alpha4beta7 integrin. N Engl J Med 2005;352:2499-507. (Pubitemid 41007865)
6. Jarnerot G, Hertervig E, Friis-Liby I, et al. Infliximab as rescue therapy in severe to moderately severe ulcerative colitis: a randomized, placebo-controlled study. Gastroenterology 2005;128:1805-11. (Pubitemid 40824691)
7. Rutgeerts P, Sandborn WJ, Feagan BG, et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med 2005;353:2462-76. (Pubitemid 41770166)
8. Sartor RB. Cytokines in intestinal inflammation: pathophysiological and clinical considerations. Gastroenterology 1994;106:533-9. (Pubitemid 24041233)
9. Braegger CP, Nicholls S, Murch SH, et al. Tumour necrosis factor alpha in stool as a marker of intestinal inflammation. Lancet 1992;339:89-91.
10. Murch SH, Braegger CP, Walker-Smith JA, et al. Location of tumour necrosis factor alpha by immunohistochemistry in chronic inflammatory bowel disease. Gut 1993;34:1705-9. (Pubitemid 23353163)
11. Murch SH, Lamkin VA, Savage MO, et al. Serum concentrations of tumour necrosis factor alpha in childhood chronic inflammatory bowel disease. Gut 1991;32:913-17.
12. Burmester GR, Mease P, Dijkmans BA, et al. Adalimumab safety and mortality rates from global clinical trials of six immune-mediated inflammatory diseases. Ann Rheum Dis 2009;68:1863-9.
13. Afif W, Leighton JA, Hanauer SB, et al. Open-label study of adalimumab in patients with ulcerative colitis including those with prior loss of response or intolerance to infliximab. Inflamm Bowel Dis 2009;15:1302-7.
14. Barreiro-de Acosta M, Lorenzo A, Dominguez-Munoz JE. Adalimumab in ulcerative colitis: two cases of mucosal healing and clinical response at two years. World J Gastroenterol 2009;15:3814-16.
15. Peyrin-Biroulet L, Laclotte C, Roblin X, et al. Adalimumab induction therapy for ulcerative colitis with intolerance or lost response to infliximab: an open-label study. World J Gastroenterol 2007;13:2328-32. (Pubitemid 46860734)
16. Schroeder KW, Tremaine WJ, Ilstrup DM. Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study. N Engl J Med 1987;317:1625-9. (Pubitemid 18010466)
17. Targan SR, Hanauer SB, van Deventer SJ, et al. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor-alpha for Crohn's disease. N Engl J Med 1997;337:1029-35.
18. Colombel JF, Sandborn WJ, Rutgeerts P, et al. Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial. Gastroenterology 2007;132:52-65. (Pubitemid 46108762)
19. Hanauer SB, Sandborn WJ, Rutgeerts P, et al. Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: the CLASSIC-I trial. Gastroenterology 2006;130:323-33.
20. Sandborn WJ, Rutgeerts P, Enns R, et al. Adalimumab induction therapy for Crohn disease previously treated with infliximab: a randomized trial. Ann Intern Med 2007;146:829-38. (Pubitemid 351650483)
21. Garud S, Brown A, Cheifetz A, et al. Meta-analysis of the placebo response in ulcerative colitis. Dig Dis Sci 2008;53:875-91. (Pubitemid 351379818)
22. Ilnyckyj A, Shanahan F, Anton PA, et al. Quantification of the placebo response in ulcerative colitis. Gastroenterology 1997;112:1854-8. (Pubitemid 27240770)
23. Finniss DG, Kaptchuk TJ, Miller F, et al. Biological, clinical, and ethical advances of placebo effects. Lancet 2010;375:686-95.